QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)

Ligand Pharmaceuticals (LGND) Competitors

$72.67
+0.30 (+0.41%)
(As of 02/21/2024 ET)

LGND vs. GERN, INVA, MNKD, DVAX, OPK, LXRX, CMPS, TVTX, NRIX, and STTK

Should you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include Geron (GERN), Innoviva (INVA), MannKind (MNKD), Dynavax Technologies (DVAX), OPKO Health (OPK), Lexicon Pharmaceuticals (LXRX), COMPASS Pathways (CMPS), Travere Therapeutics (TVTX), Nurix Therapeutics (NRIX), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical preparations" industry.

Ligand Pharmaceuticals vs.

Geron (NASDAQ:GERN) and Ligand Pharmaceuticals (NASDAQ:LGND) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

In the previous week, Geron had 6 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 9 mentions for Geron and 3 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.21 beat Geron's score of 0.00 indicating that Geron is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Geron
1 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ligand Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Geron has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.

Geron presently has a consensus price target of $4.67, suggesting a potential upside of 141.80%. Ligand Pharmaceuticals has a consensus price target of $116.33, suggesting a potential upside of 61.98%. Given Ligand Pharmaceuticals' higher possible upside, analysts clearly believe Geron is more favorable than Ligand Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geron
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ligand Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Ligand Pharmaceuticals received 57 more outperform votes than Geron when rated by MarketBeat users. Likewise, 69.84% of users gave Ligand Pharmaceuticals an outperform vote while only 69.26% of users gave Geron an outperform vote.

CompanyUnderperformOutperform
GeronOutperform Votes
471
69.26%
Underperform Votes
209
30.74%
Ligand PharmaceuticalsOutperform Votes
528
69.84%
Underperform Votes
228
30.16%

Ligand Pharmaceuticals has a net margin of 9.09% compared to Ligand Pharmaceuticals' net margin of -55,138.49%. Geron's return on equity of 9.67% beat Ligand Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Geron-55,138.49% -70.26% -48.43%
Ligand Pharmaceuticals 9.09%9.67%8.03%

Ligand Pharmaceuticals has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$317K3,306.35-$141.90M-$0.34-5.68
Ligand Pharmaceuticals$196.24M6.42-$33.36M$0.68106.87

65.4% of Geron shares are held by institutional investors. Comparatively, 89.2% of Ligand Pharmaceuticals shares are held by institutional investors. 3.1% of Geron shares are held by company insiders. Comparatively, 10.4% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Ligand Pharmaceuticals beats Geron on 12 of the 16 factors compared between the two stocks.


Get Ligand Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LGND vs. The Competition

MetricLigand PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.26B$6.58B$4.92B$7.32B
Dividend YieldN/A2.75%2.92%3.85%
P/E Ratio106.8711.37101.4516.01
Price / Sales6.42141.863,114.9857.68
Price / Cash14.4818.3589.4954.00
Price / Book2.054.404.284.56
Net Income-$33.36M$155.91M$111.66M$206.97M
7 Day Performance-1.29%1.25%1.50%0.59%
1 Month Performance0.21%9.92%7.07%4.43%
1 Year Performance2.53%-0.56%7.08%3.69%

Ligand Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GERN
Geron
3.3067 of 5 stars
$1.95
-3.0%
$4.67
+139.3%
-30.6%$1.06B$600,000.00-5.74107News Coverage
Gap Down
INVA
Innoviva
1.8344 of 5 stars
$15.80
-0.4%
$15.17
-4.0%
+27.2%$1.01B$331.34M35.91101Upcoming Earnings
MNKD
MannKind
1.7103 of 5 stars
$3.60
-1.4%
$7.50
+108.3%
-36.1%$970.49M$99.77M-30.00391Upcoming Earnings
News Coverage
Positive News
Gap Down
DVAX
Dynavax Technologies
4.5373 of 5 stars
$12.28
-1.0%
$25.00
+103.6%
+10.6%$1.60B$361.18M31.49351Upcoming Earnings
OPK
OPKO Health
4.4083 of 5 stars
$1.03
+2.0%
$3.85
+273.8%
-12.7%$796.25M$1.00B-3.814,196Upcoming Earnings
Insider Buying
LXRX
Lexicon Pharmaceuticals
1.1116 of 5 stars
$2.65
-16.7%
$4.00
+50.9%
+9.1%$778.86M$530,000.00-3.49135News Coverage
High Trading Volume
CMPS
COMPASS Pathways
1.3239 of 5 stars
$10.17
-3.2%
$44.00
+332.6%
+11.4%$629.32MN/A-3.93181Upcoming Earnings
Gap Down
TVTX
Travere Therapeutics
2.3623 of 5 stars
$8.28
+1.0%
$18.08
+118.3%
-53.5%$622.24M$145.24M-5.14462Gap Down
NRIX
Nurix Therapeutics
1.1295 of 5 stars
$10.09
+2.2%
$22.83
+126.3%
+3.8%$493.30M$76.99M-3.81297Analyst Report
STTK
Shattuck Labs
3.0824 of 5 stars
$9.17
-4.4%
$16.33
+78.1%
+111.8%$389.63M$650,000.00-4.09105Upcoming Earnings

Related Companies and Tools

This page (NASDAQ:LGND) was last updated on 2/21/2024 by MarketBeat.com Staff